HDAC9 and glioblastoma: Epigenetic dysregulation frequently occurs in cancer cells, including glioblastoma, and HDAC inhibitors have attracted attention as promising therapeutic agents capable of reactivating tumor suppressor factors that have been inactivated due to these abnormalities [25,26].